H
Haimai Medical
Health Tech & Medtech · Suzhou Shi, China · Founded 2021
Regenerative medical technology for cardiovascular disease surgeries MoreLess
Haimai Medical, founded in Suzhou, China, in 2021, is a developer of tissue engineering and regenerative medical technologies for cardiovascular disease surgeries. The company focuses on creating solutions that promote tissue repair and regeneration. These include allogeneic small-caliber tissue-engineered blood vessels intended for various applications such as vascular access for chronic renal failure dialysis, blood vessel replacement for lower extremity arterial trauma, and for treating lower extremity atherosclerosis and coronary heart disease bypass surgery.
The company secured its first funding in a Series A round in August 2024, led by IDG Capital. While the exact amount was undisclosed, this investment supports the company's research and development efforts in a competitive landscape.
Haimai Medical aims to provide advanced materials that can offer long-term durability for valve replacements and other cardiovascular procedures. Its product offerings are designed to address the challenges in treating complex cardiovascular conditions by providing alternatives for tissue and vessel repair. Keywords: tissue engineering, regenerative medicine, cardiovascular surgery, tissue-engineered blood vessels, chronic renal failure, vascular access, arterial trauma, atherosclerosis treatment, coronary bypass surgery, medical technology, allogeneic grafts, surgical treatments
Company overview
Haimai Medical company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Suzhou Shi, China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 20.7
Valuation & funding
Haimai Medical funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2026 | — | — | Suzhou Capital Group · BOC International | ↗ |
| SERIES A✓Equity / VC | Dec 2025 | $14M | $55M | SHC Shanghai Biomedical Fund · Silicon Valley · Puhua Capital · IDG Capital | ↗ |
| SERIES AEquity / VC | Aug 2024 | $0 | — | Beijing Huafang Investment | — |
| SEEDEquity / VC | Jul 2023 | $0 | — | Undisclosed | ↗ |
| SEEDEquity / VC | Mar 2023 | $0 | — | Undisclosed | ↗ |
| ANGELEquity / VC | Jun 2022 | Beijing Huafang Investment | ↗ |
Comparisons
Haimai Medical compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Haimai Medical's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Haimai Medical has talent and traffic
In the news
Latest news about Haimai Medical
Recent press, funding announcements, and product moves mentioning Haimai Medical — open to read from the original sources.
Market sentiment
What the market is saying about Haimai Medical
An AI-synthesized read of the highest-engagement posts about Haimai Medical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Haimai Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.